Apelin and copeptin: Two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease

Peptides

Volumn 49, Issue , 2013, Pages 1-8

  Lacquaniti, Antonio ^a,b   Chirico, Valeria ^a   Lupica, Rosaria ^a   Buemi, Antoine ^a   Loddo, Saverio ^a   Caccamo, Chiara ^b   Salis, Paola ^b   Bertani, Tullio ^b   Buemi, Michele ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

Author keywords

Apelin; Autosomal dominant polycystic kidney disease; Copeptin; Renal cyst growth; Total kidney volume; Vasopressin

Indexed keywords

APELIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; COPEPTIN; DIURETIC AGENT;

ADULT; ALBUMINURIA; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; BETA 2 MICROGLOBULIN URINE LEVEL; BODY MASS; CANCER INCIDENCE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KAPLAN MEIER METHOD; KIDNEY CYST; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOKING; SURVIVAL RATE; URINE OSMOLALITY;

APELIN; AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE; COPEPTIN; RENAL CYST GROWTH; TOTAL KIDNEY VOLUME; VASOPRESSIN;

ADULT; BIOLOGICAL MARKERS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPEPTIDES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROPORTIONAL HAZARDS MODELS; RENAL REPLACEMENT THERAPY;

EID: 84883532842     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2013.08.007     Document Type: Article

References (22)

1. W.E. Boertien, E. Meijer, J. Li, J.E. Bost, J. Struck, and M.F. Flessner Consortium for radiologic imaging studies of polycystic kidney disease (CRISP). Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort Am J Kidney Dis 61 2013 420 429
2. W.E. Boertien, E. Meijer, D. Zittema, M.A. van Dijk, T.J. Rabelink, and M.H. Breuning Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease Nephrol Dial Transplant 27 2012 4131 4137
3. A.B. Chapman, L.M. Guay-Woodford, J.J. Grantham, V.E. Torres, K.T. Bae, and D.A. Baumgarten Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort Kidney Int 64 2003 1035 1045 (Pubitemid 37013840)
4. N. De Mota, A. Reaux-Le Goazigo, S. El Messari, N. Chartrel, D. Roesch, and C. Dujardin Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release Proc Natl Acad Sci U S A 101 2004 10464 10469 (Pubitemid 38924948)
5. P.A. Gabow, W.D. Kaehny, A.M. Johnson, I.T. Duley, M. Manco-Johnson, and D.C. Lezotte The clinical utility of renal concentrating capacity in polycystic kidney disease Kidney Int 35 1989 675 680 (Pubitemid 19051769)
6. J.J. Grantham, V.E. Torres, A.B. Chapman, L.M. Guay-Woodford, K.T. Bae, and B.F. King Jr. Volume progression in polycystic kidney disease N Engl J Med 354 2006 2122 2130 (Pubitemid 43736612)
7. K. Hanaoka Guggino WB. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells J Am Soc Nephrol 11 2000 1179 1187 (Pubitemid 30416213)
8. A. Levin Identification of patients and risk factors in chronic kidney disease evaluating risk factors and therapeutic strategies Nephrol Dial Transplant 16 2001 57 60 (Pubitemid 33062125)
9. C. Llorens-Cortes, and F. Moos Apelin and vasopressin: two work better than one J Neuroendocrinol 24 2012 1085 1086
10. E. Meijer, S.J.L. Bakker, E.J. van der Jagt, G. Navis, P.E. de Jong, and J. Struck Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease Clin J Am Soc Nephrol 6 2011 361 368
11. E. Meijer, W.E. Boertien, R. Zietse, and R.T. Gansevoort Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease Kidney Blood Press Res 34 2011 235 244
12. E. Meijer, M. Rook, H. Tent, G. Navis, E.J. van der Jagt, and P.E. de Jong Early renal abnormalities in autosomal dominant polycystic kidney disease Clin J Am Soc Nephrol 5 2010 1091 1098
13. D. Ravine, R.N. Gibson, R.G. Walker, L.J. Sheffield, P. Kincaid-Smith, and D.M. Danks Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1 Lancet 343 1994 824 827 (Pubitemid 24147512)
14. A. Reaux, N. De Mota, I. Skultetyova, Z. Lenkei, S. El Messari, and K. Gallatz Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain J Neurochem 77 2001 1085 1096 (Pubitemid 32467063)
15. A. Reaux-Le Goazigo, A. Morinville, C. Burlet Llorens-Cortes, and A. Beaudet Dehydration-induced cross-regulation of apelin and vasopressin immunoreactivity levels in magnocellular hypothalamic neurons Endocrinology 145 2004 4392 4400 (Pubitemid 39120589)
16. P. Ruggenenti, F. Gaspari, A. Cannata, F. Carrara, C. Cella, and S. Ferrari Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study PLoS ONE 7 2012 e32533
17. G. Szinnai, N.G. Morgenthaler, K. Berneis, J. Struck, B. Müller, and U. Keller Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects J Clin Endocrinol Metab 92 2007 3973 3978 (Pubitemid 47607649)
18. V.E. Torres, A.B. Chapman, O. Devuyst, R.T. Gansevoort, J.J. Grantham, and E. Higashihara Tolvaptan in patients with autosomal dominant polycystic kidney disease N Engl J Med 367 2012 2407 2418
19. V.E. Torres, J.J. Grantham, A.B. Chapman, M. Mrug, K.T. Bae, and B.F. King Jr. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease Clin J Am Soc Nephrol 6 2011 640 647
20. Work group and evidence review team membership K/DOQI clinical practice guidelines on chronic kidney disease Am J Kidney Dis 39 2002 S1 S216
21. H.H. Zingg, D. Lefebvre, and G. Almazan Regulation of vasopressin gene expression in rat hypothalamic neurons. Response to osmotic stimulation J Biol Chem 261 1986 12956 12959 (Pubitemid 17006861)
22. D. Zittema, W.E. Boertien, A.P. van Beek, R.P. Dullaart, C.F. Franssen, and P.E. de Jong Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment Clin J Am Soc Nephrol 7 2012 906 913